Business, energy, technology, markets and global industry news from Business News Today

Affinia Therapeutics

PharmaDeviceNews Affinia Therapeutics
Editorial infographic illustrating Affinia Therapeutics’ AFTX-201 BAG3 heart gene therapy programme, featuring an anatomical heart, DNA strands and clinical research imagery, with highlights on the 22-patient trial, promising animal results and unproven human safety and efficacy.
Pharma & Biotech

Affinia presents AFTX-201 preclinical data and UPBEAT trial design at HFSA 2026

Affinia advances AFTX-201 into a 22-patient BAG3 heart gene therapy trial after promising animal results. Human safety and efficacy remain unproven.

Read More
Affinia Therapeutics’ AFTX-201 gene therapy is advancing through the UPBEAT trial after receiving FDA Orphan Drug designation for BAG3-associated dilated cardiomyopathy. Representative image.
Pharma & Biotech

Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy

Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.

Read More
Pharma & Biotech

What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy

Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.

Read More
FDA Fast Track for AFTX-201 raises new expectations for gene therapy in BAG3 cardiomyopathy
Pharma & Biotech

Affinia Therapeutics’ AFTX-201 Fast Track decision highlights rising interest in cardiac gene therapy

Affinia Therapeutics’ AFTX-201 wins FDA Fast Track for BAG3 cardiomyopathy. Explore what this means for cardiac gene therapy and future heart failure treatments.

Read More